Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 8/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692383 | 0.89 | AHCY (0.54) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL6697082 | 0.88 | AHCY (0.52) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5685760 | 0.87 | AHCY (0.54) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL7924078 | 0.87 | AHCY (0.53) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1068915 | 0.85 | AHCY (0.60) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1093486 | 0.81 | EHMT1 (0.56) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5354507 | 0.78 | ADORA3 (0.56) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL6406587 | 0.77 | AHCY (0.56) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL19066616 | 0.76 | AHCY (0.58) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL10687080 | 0.75 | ADORA3 (0.59) | AHCYADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242531-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADERIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| US-20040242930-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADERIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| US-6784165-B1 | ADENOSINE A1 RECEPTOR AGONISTS | ADERIS PHARMACEUTICALS, INC. | 2004-08-31 | — | — | US | claimed |
| EP-1239864-A1 | TREATMENT OF HEART RHYTHM DISTURBANCES WITH N6 -SUBSTITUTED-5'-(N-SUBSTITUTED) CARBOXAMIDOADENOSINES | Aderis Pharmaceuticals, Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| WO-2001037845-A1 | TREATMENT OF HEART RHYTHM DISTURBANCES WITH N6-SUBSTITUTED-5'-(N-SUBSTITUTED) CARBOXAMIDOADENOSINES | ADERIS PHARMACEUTICALS, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| US-20040242531-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADERIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242930-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADERIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-6784165-B1 | ADENOSINE A1 RECEPTOR AGONISTS | ADERIS PHARMACEUTICALS, INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1239864-A1 | TREATMENT OF HEART RHYTHM DISTURBANCES WITH N6 -SUBSTITUTED-5'-(N-SUBSTITUTED) CARBOXAMIDOADENOSINES | Aderis Pharmaceuticals, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001037845-A1 | TREATMENT OF HEART RHYTHM DISTURBANCES WITH N6-SUBSTITUTED-5'-(N-SUBSTITUTED) CARBOXAMIDOADENOSINES | ADERIS PHARMACEUTICALS, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242930-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADRA1D, ADORA1, ADRA2C | AHCY 598/4885ADORA3 5/4885ADORA2A 6/4885 |
| US-20040242531-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADRA1D, ADORA1, ADRA2C | AHCY 598/4885ADORA3 5/4885ADORA2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.